{"id":"NCT03549871","sponsor":"Genzyme, a Sanofi Company","briefTitle":"A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis","officialTitle":"ATLAS-PPX: an Open-label, Multinational, Switching Study to Describe the Efficacy and Safety of Fitusiran Prophylaxis in Patients With Hemophilia A and B Previously Receiving Factor or Bypassing Agent Prophylaxis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-25","primaryCompletion":"2022-01-20","completion":"2022-03-25","firstPosted":"2018-06-08","resultsPosted":"2023-02-06","lastUpdate":"2023-02-06"},"enrollment":80,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia"],"interventions":[{"type":"DRUG","name":"Fitusiran","otherNames":[]},{"type":"DRUG","name":"BPA prophylaxis","otherNames":[]},{"type":"DRUG","name":"Factor (FVIII or FIX) prophylaxis","otherNames":[]}],"arms":[{"label":"Fitusiran","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo characterize the frequency of bleeding episodes (BE) while receiving fitusiran treatment, relative to the frequency of bleeding episodes while receiving factor concentrate or bypassing agent (BPA) prophylaxis.\n\nSecondary Objectives:\n\n* To characterize the following while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis:\n* the frequency of spontaneous bleeding episodes\n* the frequency of joint bleeding episodes\n* health related quality of life (HRQOL) in participants greater than or equal to (\\>=) 17 years of age\n* To characterize the frequency of bleeding episodes during the onset and treatment periods in participants receiving fitusiran.\n* To characterize the safety and tolerability of fitusiran.\n* To characterize the annualized weight-adjusted consumption of factor/BPA while receiving fitusiran treatment, relative to receiving factor or BPA prophylaxis.","primaryOutcome":{"measure":"Estimated Annualized Bleeding Rate (ABR)","timeFrame":"Factor/BPA prophylaxis period: Day -168 to Day -1 or up to last day of bleeding follow up (any day up to Day -1); 6-month fitusiran efficacy period: Day 29 to Day 190 or up to last day of bleeding follow up (any day up to Day 190), whichever was earliest","effectByArm":[{"arm":"Overall Factor/BPA Prophylaxis Period","deltaMin":7.482,"sd":null},{"arm":"Overall Fitusiran 80 mg Efficacy Period","deltaMin":2.908,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.0008"}]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":16,"exclusionCount":12},"locations":{"siteCount":35,"countries":["United States","Australia","China","Denmark","France","Ireland","Israel","Italy","Japan","Malaysia","Mexico","South Korea","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38452197"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":19},"commonTop":["Alanine Aminotransferase Increased","Upper Respiratory Tract Infection","Arthralgia","Nasopharyngitis","Fibrin D Dimer Increased"]}}